Susan G Komen  
I've Been Diagnosed With Breast Cancer Someone I Know Was Diagnosed Share Your Story Join Us And Stay Informed Donate To End Breast Cancer
Home > Understanding Breast Cancer > Breast Cancer Research > Table 56: Menopausal hormone therapy after breast cancer diagnosis and recurrence

  


Table 56: Menopausal hormone therapy after breast cancer diagnosis and recurrence

This summary table contains detailed information about research studies. Summary tables offer an informative look at the science behind many breast cancer guidelines and recommendations. However, they should be viewed with some caution. In order to read and interpret research tables successfully, it is important to understand some key concepts. Learn how to read a research table.

Introduction: Menopausal hormone therapy (MHT) increases the risk of developing breast cancer (see Table 8) [1]. For this reason, all women, including breast cancer survivors, are advised to avoid long-term use of MHT.

Findings from large randomized controlled trials have shown an increased risk of breast cancer recurrence, metastasis or cancer in the opposite breast in women who used MHT after breast cancer diagnosis compared to those who did not [2-3]. 

Learn about the strengths and weaknesses of different types of studies.  

Study selection criteria: Randomized controlled trials.

Table note: Relative risk above 1 indicates increased risk. Relative risk below 1 indicates decreased risk.

Study 

Study Population
(number of participants)
 

Follow-up
(months)
 

Relative Risk of a Breast Cancer Event 
Among Women Who Used Menopausal Hormone
Therapy after Breast Cancer Compared to
Those Who Did Not,
RR (95% CI)
 

Randomized controlled trials   

Holmberg et al. [2]

442

48

Recurrence, metastasis or
cancer in the opposite breast:
2.2 (1.0-5.1)

Fahlén et al. [3]

378

130

Recurrence:
0.8 (0.3-1.7)

Metastasis:
1.0 (0.5-2.3)

Cancer in the opposite breast:
3.3 (1.2-10.9)


References  

1. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288(3):321-33, 2002.

2. Holmberg L, Iverson OE, Rudenstam CM, et al., for the HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 100(7):475-82, 2008.

3. Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 49(1):52-9, 2013.

Updated 04/30/13